Protective role of fibrates in cardiac ischemia/reperfusion

Journal of Advanced Pharmaceutical Technology and Research

Volumn 3, Issue 3, 2012, Pages 188-192

  Sugga, G S ^a   Khan, M U ^a,b   Khanam, R ^c  

^a NIMS UNIVERSITY   (India)

^b Sri Sai College of Pharmacy   (India)

^c HAMDARD UNIVERSITY   (India)

Author keywords

Clofibrate; fenofibrate; I R injury; oxidative stress; PPAR a

Indexed keywords

CLOFIBRATE; CREATINE KINASE; FENOFIBRATE; GLUTATHIONE; LACTATE DEHYDROGENASE; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE SEVERITY; ENZYME RELEASE; FEMALE; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; ISOLATED HEART; LACTATE DEHYDROGENASE BLOOD LEVEL; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

EID: 84866405560     PISSN: 22314040     EISSN: 09762094     Source Type: Journal    
DOI: 10.4103/2231-4040.101016     Document Type: Conference Paper

References (23)

1. Sarapultsev P, Chupakhin O, Sarapultsev A, Rantsev M, Sidorova L, Medvedeva S, et al. New insights in to the treatment of myocardial infarction. Int J Exp Pathol 2012;93:18-23.
2. Yamazaki KG, Romero-Perez D, Barraza-Hidalgo M, Cruz M, Rivas M, Cortez-Gomez B, et al. Short-and long-term effects of (-)-epicatechin on myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2008;295:H761-7.
3. Lochner A, Marais E, Genade S, Huisamen B, du Toit EF, Moolman JA. Protection of the ischaemic heart: Investigations into the phenomenon of ischaemic preconditioning. Cardiovasc J Afr 2009;20:43-51.
4. Singh G, Rohilla A, Rohilla S, Kumar A, Khan MU, Khanam R. Fibrates: The best modifying strategy for dyslipidemias. Cardiovasc Diabetol 2011;3:134-40.
5. Antonenkov VD, Gusev VA, Panchenko LF. Effect of clofibrate treatment on glutathione content and the activity of the enzymes related to peroxide metabolism in rat liver and heart. Int J Biochem 1987;19:187-92.
6. Bogdanska JJ, Todorova B, Labudovic D, Atanasovska E. Effect of clofibrate on the enzymes associated with oxidative stress in Wistar rat liver. Bratisl Lek Listy 2007;108:56-64.
7. Newaz M, Ranganna K, Truong L, Oyekan A. Effect of peroxisome proliferator-activated receptor-[alpha] siRNA on hypertension and renal injury in the rat following nitric oxide withdrawal and high salt diet. J Hypertens 2009;27:2223-31.
8. Goya K, Sumitani S, Xu X. Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2004;24:658-63.
9. Balakumar P, Rohilla A, Mahadevan N. Pleiotropic actions of fenofibrate on the heart. Pharmacol Res 2011;63:8-12.
10. Koh KK, Quon MJ, Han SH. Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. Diabetes Care 2006;29:195-201.
11. Langend or ffO. Untersuc hungenamu berlebenden Saugethierherzen. Archiv fur die gesammte Physiologie des Menschen und der Thiere Bonn 1895;61:291-332.
12. Krebs HA, Henseleit K. Untersuchungen uber die Harnstoffbildung im Tierkorper. Hoppe-Seyler's Zeitschrift für. Physiol Chemie 1932;210:33-66.
13. Parikh V, Singh M. Possible role of adrenergic component and cardiac mast cell degranulation in preconditioning-induced cardioprotection. Pharmacol Res 1999;40:129-37.
14. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8.
15. Wang HD, Pagano PJ, Du Y, Cayatte AJ, Quinn MT, Brecher P, et al. Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide. Circ Res 1998;82:810-8.
16. Beutler E, Duron O, Kefly BM. Improved method for the determination of blood glutathione. J Lab Clin Med 1963;61:882-8.
17. Goldfine AB, Kaul S, Hiatt WR. Fibrates in the treatment of dyslipidemias-time for a reassessment. N Engl J Med 2011;365:481-4.
18. Stolarczyk M, Gutman W, Derlacz RA. Nuclear receptors PPAR as a drug target in metabolic disorders. Postepy Biochem 2011;57:207-14.
19. Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. J Adv Pharm Technol Res 2011;2:236-40.
20. Fazio S. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: A role for combination fibrate therapy. Clin Ther 2008;30:294-306.
21. Kaur H, Parikh V, Sharma A, Singh M. Effect of amiloride a Na +H+ exchange inhibitor on cardioprotective effect of ischaemic preconditioning: Possible involvement of resident cardiac mast cells. Pharmacol Res 1997;36:95-102.
22. Singh G, Rohilla A, Singh M, Balakumar P. Possible role of JAK-2 in attenuated cardioprotective effect of ischemic preconditioning in Hyperhomocysteinemic rat hearts. Yakugaku Zasshi 2009;129:523-35.
23. Devi S, Kennedy RH, Joseph L, Shekhawat NS, Melchert RB, Joseph J. Effect of long-term hyperhomocysteinemia on myocardial structure and function in hypertensive rats. Cardiovasc Pathol 2006;15:75-82.